Display options
Cite
Mariz FC, Bender N, Anantharaman D, et al. Peak neutralizing and cross-neutralizing antibody levels to human papillomavirus types 6/16/18/31/33/45/52/58 induced by bivalent and quadrivalent HPV vaccines. NPJ Vaccines. 2020;5(1):14doi: 10.1038/s41541-020-0165-x.
Mariz, F. C., Bender, N., Anantharaman, D., Basu, P., Bhatla, N., Pillai, M. R., Prabhu, P. R., Sankaranarayanan, R., Eriksson, T., Pawlita, M., Prager, K., Sehr, P., Waterboer, T., Müller, M., & Lehtinen, M. (2020). Peak neutralizing and cross-neutralizing antibody levels to human papillomavirus types 6/16/18/31/33/45/52/58 induced by bivalent and quadrivalent HPV vaccines. NPJ vaccines, 5(1), 14. https://doi.org/10.1038/s41541-020-0165-x
Mariz, Filipe Colaço, et al. "Peak neutralizing and cross-neutralizing antibody levels to human papillomavirus types 6/16/18/31/33/45/52/58 induced by bivalent and quadrivalent HPV vaccines." NPJ vaccines vol. 5,1 (2020): 14. doi: https://doi.org/10.1038/s41541-020-0165-x
Mariz FC, Bender N, Anantharaman D, Basu P, Bhatla N, Pillai MR, Prabhu PR, Sankaranarayanan R, Eriksson T, Pawlita M, Prager K, Sehr P, Waterboer T, Müller M, Lehtinen M. Peak neutralizing and cross-neutralizing antibody levels to human papillomavirus types 6/16/18/31/33/45/52/58 induced by bivalent and quadrivalent HPV vaccines. NPJ Vaccines. 2020 Feb 14;5(1):14. doi: 10.1038/s41541-020-0165-x. eCollection 2020. PMID: 32128255; PMCID: PMC7021830.
Copy Download .nbib Format: NLM
Share it on

NPJ Vaccines. 2020 Feb 14;5(1):14. doi: 10.1038/s41541-020-0165-x. eCollection 2020.

Peak neutralizing and cross-neutralizing antibody levels to human papillomavirus types 6/16/18/31/33/45/52/58 induced by bivalent and quadrivalent HPV vaccines.

NPJ vaccines

Filipe Colaço Mariz, Noemi Bender, Devasena Anantharaman, Partha Basu, Neerja Bhatla, Madhavan Radhakrisna Pillai, Priya R Prabhu, Rengaswamy Sankaranarayanan, Tiina Eriksson, Michael Pawlita, Kristina Prager, Peter Sehr, Tim Waterboer, Martin Müller, Matti Lehtinen

Affiliations

  1. 1Tumorvirus-Specific Vaccination Strategies, Deutsches Krebsforschungszentrum (DKFZ), 69120 Heidelberg, Germany.
  2. 2Infections and Cancer Epidemiology, Deutsches Krebsforschungszentrum (DKFZ), 69120 Heidelberg, Germany.
  3. 3Rajiv Gandhi Centre for Biotechnology, Poojappura, Thiruvananthapuram, 695014 Kerala India.
  4. 4Screening Group, International Agency for Research on Cancer (IARC), 69008 Lyon, France.
  5. 5All India Institute of Medical Sciences, 110029 New Delhi, India.
  6. Research Triangle Institute International India, 6th Floor, Pullman Commercial Tower, Aero City, 110037 New Delhi India.
  7. 7Karolinska Institute, 17177 Stockholm, Sweden.
  8. 8EMBL-DKFZ Chemical Biology Core Facility, European Molecular Biology Laboratory, 69117 Heidelberg, Germany.

PMID: 32128255 PMCID: PMC7021830 DOI: 10.1038/s41541-020-0165-x

Abstract

We performed an independent comparison of neutralizing and cross-neutralizing antibody (ab) levels seven months after initiation of three-dose, six-month vaccination schedules with the bivalent and quadrivalent human papillomavirus (HPV) vaccines in adolescent Finnish and Indian females, respectively. We used a semi-automated Pseudovirion-Based Neutralization Assay and observed significantly higher HPV16/18 peak ab-levels in bivalent as compared to quadrivalent vaccine recipients. Bivalent vaccine induced cross-neutralizing HPV31/33/45/52/58 antibodies significantly more frequently and to higher levels than the quadrivalent vaccine. The correlation of bivalent vaccine-induced HPV45 ab-levels with HPV16/18 ab-levels was stronger than that of corresponding quadrivalent vaccine-induced ab-levels, suggesting a qualitatively different cross-reactive response. Our findings on the comparison of the immunogenicity of two HPV vaccine tested in two different populations indicate that further head-to-head studies are warranted.

© The Author(s) 2020.

Keywords: Cervical cancer; Viral infection

Conflict of interest statement

Competing interestsM.L. has received grants for HPV vaccination studies from Merck Sharp & Dohme and GlaxoSmithKline Biologicals through University of Tampere. M.M., M.P. and P.S. are inventors on a p

References

  1. Oncoimmunology. 2012 Sep 1;1(6):995-996 - PubMed
  2. Gynecol Oncol. 2017 Jul;146(1):196-204 - PubMed
  3. Lancet Oncol. 2012 Jan;13(1):89-99 - PubMed
  4. J Infect Dis. 2009 Jul 15;200(2):166-71 - PubMed
  5. BMC Res Notes. 2014 Jul 11;7:445 - PubMed
  6. Lancet Infect Dis. 2017 Dec;17(12):1293-1302 - PubMed
  7. J Infect Dis. 2019 Jan 29;219(4):582-589 - PubMed
  8. Lancet Oncol. 2016 Jan;17(1):67-77 - PubMed
  9. Vaccine. 2006 Jul 7;24(27-28):5571-83 - PubMed
  10. Vaccine. 2018 Aug 6;36(32 Pt A):4792-4799 - PubMed
  11. J Infect Dis. 2018 Apr 23;217(10):1579-1589 - PubMed
  12. Jpn J Clin Oncol. 2017 Mar 1;47(3):265-276 - PubMed
  13. Lancet. 2017 Nov 11;390(10108):2143-2159 - PubMed
  14. Vaccine. 2016 Mar 18;34(13):1559-1565 - PubMed
  15. PLoS One. 2013 Oct 04;8(10):e75677 - PubMed
  16. Nat Rev Clin Oncol. 2013 Jul;10(7):400-10 - PubMed
  17. Clin Vaccine Immunol. 2015 Apr;22(4):361-73 - PubMed
  18. J Infect Dis. 2019 Aug 30;220(7):1141-1146 - PubMed
  19. PLoS One. 2013 May 01;8(5):e61825 - PubMed
  20. J Infect Dis. 2019 Jan 9;219(3):382-390 - PubMed
  21. Clin Vaccine Immunol. 2015 Aug;22(8):943-8 - PubMed
  22. N Engl J Med. 2007 May 10;356(19):1915-27 - PubMed
  23. Expert Rev Vaccines. 2018 Dec;17(12):1085-1091 - PubMed

Publication Types